Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Qu...( regulatory filings and actions and Onyx...),Health

Date:11/3/2009

, regulatory filings and actions and Onyx's anticipated acquisition of Proteolix, Inc. and its lead product candidate, carfilzomib. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: Nexavar being our only approved product; competition; failures or delays in our clinical trials; dependence on our collaborative relationship with Bayer; market acceptance and the rate of adoption of our products; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; the indebtedness incurred through the sale of our 4.0% convertible senior notes due 2016; product liability risks; and the consummation and anticipated benefits of the proposed acquisition of Proteolix. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission, under the heading "Risk Factors" for a more detailed description of these and other risks, as well as the company's subsequent quarterly reports on Form 10Q. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

                           (See attached tables.)


                        ONYX PHARMACEUTICALS, INC.
                    CONDENSED STATEMENTS OF OPERATIONS
                 (In thousands, except per share amounts)
                                (unaudited)

                    
'/>"/>
SOURCE  Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 
Related medicine news :

1. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
2. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
3. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
4. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
5. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
6. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
7. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
8. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
9. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
10. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
11. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference